EN DE
STOCK COMPARISON

Abbott Laboratories vs UnitedHealth Group: Fair Value & Quality

Both stocks run through our valuation models. Here is how Abbott Laboratories (ABT) and UnitedHealth Group (UNH) compare, as of Oct 20, 2026.

As of Oct 20, 2026, Fair Value Calculator sees UnitedHealth Group as the more attractively valued of the two: Abbott Laboratories trades at $104 versus a fair value of $74.79 (−28.1%), while UnitedHealth Group trades at $407 versus $532 (+30.7%).
Abbott Laboratories
ABT · USD · Health Care
−28.1%
upside to fair value
overvalued
Price$104
Fair Value$74.79
Quality66/100
UnitedHealth Group
UNH · USD · Health Care
+30.7%
upside to fair value
undervalued
Price$407
Fair Value$532
Quality61/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

Abbott LaboratoriesUnitedHealth Group
Valuation
34.5×P/E (TTM)26.2×
27.9×P/E ex one-offs (FY2025)29.1×
17.2×Forward P/E (FY2027)18.0×
35.6×Median P/E at FY-end (ex one-offs where documented)22.1×
3.89×P/S (TTM)0.82×
3.48×P/B3.92× · book value is mostly goodwill
15.7×EV/EBITDA14.4×
1.90×PEG1.01×
−28.1%Fair value upside+30.7%
2.4%Dividend yield0.5%
$2.48Dividend per share$2.21
Profitability
14.7%Operating margin5.8%
1.19×EBIT margin trend (5Y)0.48×
10.6%Return on equity15.8%
7.5%Return on assets3.9%
Growth
13.0%Revenue growth (YoY)-0.4%
0.5%Avg. growth/yr (3Y)11.4%
5.1%Avg. growth/yr (5Y)11.7%
+10.6%Value creation/yr−2.2%
Balance & size
23.6×Interest coverage (EBIT/interest)4.7×
0.19×Debt / equity0.77×
$181BMarket cap$369B
healthyGrowth qualitymixed
The P/E excluding one-off items is only shown where the special items are documented in the accounts (our own raw data or SEC filings). If one side lacks it, the reported P/E stays scored.
Abbott Laboratories, median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings, FY2016, FY2020, FY2023 ex one-offs: 35.6. UnitedHealth Group, median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, 4 of the years ex one-offs: 22.1.
Forward P/E: price divided by the analyst consensus for the first fiscal year that has not started yet. The current year carries special items from quarters already reported.

Abbott Laboratories leads: 8 to 7 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Abbott Laboratories UnitedHealth Group
ProfitabilityHow much profit the company makes from its sales and capital
50
52
Quality GrowthAre margins and returns getting better?
47
48
CashflowDo the profits arrive as real cash?
71
52
Financial strengthDebt, balance sheet and risk of trouble
80
51
InvestmentDoes it invest with discipline instead of growing at any price?
65
76
Low VolatilityHow calm the share price moves, does not count
83
73
MomentumPrice trend of the last 3 to 12 months, does not count
39
53
Near the 52-week highDistance to the 52-week high, does not count
31
69
New sharesBuys back shares or issues new ones?
83
90

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyAbbott LaboratoriesPrice $104UnitedHealth GroupPrice $407
DCF Models−22.2%below the price$80.93+10.0%close to the price$448
Earnings-Based−70.1%below the price$31.13−51.4%below the price$198
Dividend Discount−56.9%below the price$44.90n/a
Multiples−33.5%below the price$69.23−27.4%below the price$295
Asset-Based−91.7%below the price$8.68n/a
Growth DCF−28.8%below the price$74.09+22.4%above the price$498
Economic Profit−60.8%below the price$40.75−47.7%below the price$213
Growth Earnings−32.5%below the price$70.25−27.4%below the price$295
Minimum−91.7%below the price$8.68−51.4%below the price$198
Maximum−22.2%below the price$80.93+22.4%above the price$498
Median−45.2%below the price$57.07−27.4%below the price$295
Geometric mean−57.6%below the price$44.14−24.8%below the price$306

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Abbott Laboratories: 26 of 26 models see the stock below the current price.

UnitedHealth Group: 15 of 22 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Abbott Laboratories
Price $104
Fair Value $74.79
Bear $52.28Bull $94.43
UnitedHealth Group
Price $407
Fair Value $532
Bear $377Bull $691

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Abbott Laboratories · Health Care

Quality score66 · Top 25%
Fair value upside−28.1% · below median

UnitedHealth Group · Health Care

Quality score61 · above median
Fair value upside+30.7% · Top 25%

Bottom line

As of Oct 20, 2026, Fair Value Calculator sees UnitedHealth Group as the more attractively valued of the two: Abbott Laboratories trades at $104 versus a fair value of $74.79 (−28.1%), while UnitedHealth Group trades at $407 versus $532 (+30.7%).

Abbott Laboratories has the higher quality score (66/100).

Open UnitedHealth Group live analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.